Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 16
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
DexCom Inc
DXCM
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$87.71
4.24
5.08%
Dern. MÀJ: Oct 15, 4:39 PM
$87.62
4.15
4.97%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Résultats:
Résultats Q3 2026 dans dans 14 jours à partir de maintenant le jeu. oct. 29th, après la fermeture du marché
DexCom Financials
DexCom (DXCM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
DexCom Raises FY2026 Sales Guidance from $5.160B-$5.250B to $5.180B-$5.250B vs $5.224B Est
DexCom (NASDAQ:DXCM) raises FY2026 sales outlook from $5.160 billion-$5.250 billion to $5.180 billion-$5.250 billion vs $5.224 billion estimate.
Benzinga Newsdesk
PRO
DexCom Q2 Adj. EPS $0.70 Beats $0.61 Estimate, Sales $1.308B Beat $1.290B Estimate
DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.61 by 14.75 percent. This is a 45.83 percent increase over earnings of $0.48 per share from the same
Benzinga Newsdesk
Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
DexCom Sets 2030 Margin Targets, Projects Double-Digit Revenue Growth, Authorizes $1 Billion Share Buyback
Vandana Singh
PRO
DexCom Affirms FY2026 Sales Guidance of $5.160B-$5.250B vs $5.230B Est
2026 Annual GuidanceDexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin, and reiterating guidance for Revenue and Non-GAAP Gross Profit Margin at the following
Benzinga Newsdesk
PRO
DexCom Q1 Adj. EPS $0.56 Beats $0.47 Estimate, Sales $1.191B Beat $1.175B Estimate
DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.47 by 19.15 percent. This is a 75 percent increase over earnings of $0.32 per share from the same period
Benzinga Newsdesk
Earnings Scheduled For April 30, 2026
Benzinga Insights
